治疗氨引起的肺损伤的挑战和复杂性:氨会破坏细胞膜并引发严重损伤
Gregory Rankin1, Terese Karlsson1, Åsa Gustafsson1
1Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden.
Inhalation toxicology
|December 4, 2025
概括
吸入氨气会导致严重的肺损伤,目前的治疗方法提供有限的保护. 新的研究表明,甲是无效的,但稳定细胞膜可能有助于减轻氨引起的损伤.
科学领域:
- 毒理学 毒理学 毒理学
- 肺部医学 肺部医学
- 细胞生物学 细胞生物学
背景情况:
- 吸入氨 (NH3) 是一种常见的职业危险,导致急性肺损伤 (ALI).
- 目前对吸入氨的医疗治疗主要是辅助的,缺乏特定的抗药.
- 这项研究研究了NH3诱导的肺损伤的潜在治疗干预措施.
研究的目的:
- 评估治疗干预措施对氨引起的肺损伤的疗效.
- 在动物和细胞模型中评估甲和其他药物的保护作用.
- 了解NH3毒性的机制,并确定潜在的治疗策略.
主要方法:
- BALB/c小鼠被暴露在氨 (NH3) 中,并接受了甲治疗.
- 在体外研究中使用A549膜上皮细胞来检查NH3的毒性.
- 评估包括ALI严重程度,炎症标志物,细胞活力和氧化应激.
主要成果:
- 德克萨米他治疗并没有预防致命损伤,也没有显著降低小鼠的ALI严重程度.
- 氨暴露导致肺炎,出血和凝血异常的增加.
- 在试验室中,Poloxamer 188显示出稳定细胞膜的潜力,防止氨引起的损伤.
结论:
- 皮质类固醇对氨引起的肺损伤提供有限的保护.
- 试验室研究揭示了NH3毒性的复杂性,强调了细胞膜完整性.
- 对于吸入氨的伤害,有必要制定有效的医疗对策.
更多相关视频
09:16Open Tracheostomy Gastric Acid Aspiration Murine Model of Acute Lung Injury Results in Maximal Acute Nonlethal Lung Injury
Published on: February 26, 2017
10.1K
14:48Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
5.5K
相关概念视频
Urea Cycle
49.5K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
49.5K
Acute Respiratory Failure-V
425
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
425
Acute Respiratory Failure-III
733
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
733
Toxic Reactions: Overview
1.8K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.8K
Anticholinesterase Agents: Poisoning and Treatment
1.5K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.5K
Acute Respiratory Failure-II
988
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
988
